Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pterygium: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Pterygium: 4 US clinical trials tracked, none currently recruiting.
Pterygium is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Suzhou Raymon Pharmaceuticals Company, running 1 of these trials.
Enrollment posture brief
Registry condition pterygium
OPEN 0 | RECR 0% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Pterygium has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pterygium on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pterygium is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
Cloudbreak Therapeutics
NCT05456425
RMP-A03 Ocular Suspension in Patients With Pterygium
Suzhou Raymon Pharmaceuticals Company
NCT05794204
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
The University of Texas Health Science Center, Houston
NCT01115517
Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
University of New Mexi
NCT01169909
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pterygium records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pterygium trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pterygium page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Pterygium trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Suzhou Raymon Pharmaceuticals Company sponsors the most Pterygium trials on record, review their full trial history before evaluating a specific study. See Suzhou Raymon Pharmaceuticals Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pterygium condition card totals 4 registered trials; most-linked intervention RMP-A03 Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.